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Essentials
• Fc-fusion increases a therapeutic's half-life, but FccR interactions may impact immunogenicity.
• Species-specific Fc-FccR interactions allow for mechanistic in vivo studies using mouse models.
• Fc fusion modulates the immune response to factor IX in hemophilia B mice by eliciting Th1 bias.
• This model could inform future studies of IgE-associated anaphylaxis in hemophilia B patients.
Summary. Background: Fc fusion is a platform technology used to increase the circulating half-life of protein and peptide therapeutics. However, there are potential immunological consequences with this approach, such as changes in the molecule's immunogenicity as well as possible interactions with a repertoire of Fc receptors (FcR) that can modulate immune responses. Objectives/Methods: Using a mouse hemophilia B (HB) model, we compared the immune responses to infusions of recombinant human factor IX (hFIX) and hFIX fused to mouse IgG2a-Fc (hFIX-mFc). The mFc was employed to allow speciesspecific Fc-FccR interactions. Results: Although treatment with hFIX-mFc altered the early development of anti-FIX IgG, no significant differences in anti-FIX antibody titers were observed at the end of the treatment regimen (5 weeks) or upon anamnestic response (5 months). However, treatment with hFIX-mFc elicited higher FIX-neutralizing antibody levels and resulted in reduced IgE titers compared with the hFIX-treated group. Additionally, differences in plasma cytokine levels and in vitro CD4 + T-cell responses suggest that whereas hFIX treatment triggered a Th2-biased immune response, hFIX-mFc treatment induced Th1-biased CD4 + T cells. We also show that hFIX-mFc bound to soluble FccRs and engaged with FccRs on different cell types, which may impact antigen presentation. Conclusions: These studies provide a model system to study how Fc-fusion proteins may affect immune mechanisms. We used this model to demonstrateIntroduction Some bioengineering strategies are broadly applicable to different protein-drugs across therapeutic areas. Among these platform technologies, Fc fusion is one of the most successful, whether measured by the number of products approved, application to diverse disease areas or the value of global sales [1] [2] [3] . Fc fusions exploit a key biological property of the immunoglobulin constant region (Fcdomain) of IgG antibodies. The Fc-domain salvages IgG from endosomal degradation by binding to the neonatal Fc receptor (FcRn) facilitating recycling [4] . Thus the Fcdomain, genetically fused to a protein of therapeutic interest, increases its plasma half-life [5] . Recently, the FDA granted approval to Fc fusion analogs of two coagulation proteins, factor VIII (FVIII) and factor IX (FIX), developed because current recombinant products have short circulating half-lives necessitating frequent infusions [6, 7] .
In the treatment of hemophilia A and B, the development of neutralizing anti-drug antibodies (nADA) (or inhibitors) to FVIII or FIX is one of the most significant impediments to the management of these diseases [8, 9] . Moreover, anaphylaxis is a rare yet potentially life-threatening adverse event associated with hFIX treatment of HB patients [10, 11] . Evaluation of the FVIII and FIX Fcfusion analogs for immunogenicity during drug development and clinical studies indicates that these drugs are comparable to existing products in previously treated patients [12, 13] .
Fc biology is complex. Although the Fc domain has been shown to exert an anti-inflammatory and tolerogenic effect [14] [15] [16] [17] [18] , this domain can also target fusion-proteins to antigen presenting cells (APC) such as macrophages (MΦ), dendritic cells (DC), B cells and monocytes, as well as to granulocytes, mast cells and natural killer (NK) cells that express activation and inhibitory Fc receptors (FccR), which can potentially trigger or inhibit immunity and inflammation [19] [20] [21] [22] (for comprehensive discussion see [23] ). Therefore, it is important to understand the underlying biology of how the Fc moiety, as part of fusion proteins, affects immunological responses. Although clinical studies are useful for monitoring outcomes they cannot provide detailed mechanistic insights. Given the complexity of the immune response and the diversity of Fc-FcR interactions, in vitro and ex vivo studies have limited utility in understanding the physiological consequences.
In this study we have characterized a model system that could be beneficial for studying Fc-fusion proteins. We used a mouse model for hemophilia B and have engineered a recombinant chimeric human-FIX-mouse-Fc (hFIXmFc) protein capable of engaging with murine FccRs to understand the effect of Fc fusion on the immunogenicity of FIX. The treatment regimen was designed to reflect clinical practice in terms of dose, route of administration and frequency [24] . Our results show that Fc fusion alters the development of anti-FIX and inhibitory antibodies. Consistent with previous studies [25, 26] , treatment with hFIX induces elevation in IgE. Interestingly, treatment with hFIX-mFc results in lower IgE levels and exhibits a Th1 bias. Using this model we demonstrate that, for FIX therapeutics, Fc fusion can alter the Th2 bias of anti-FIX immune responses. This proof-of-principle study establishes a model system to investigate immunological mechanisms affected by Fc fusion.
Methods

Expression and purification of hFIX-mFc
Expression and purification of hFIX-mFc was performed using similar procedures to those used for hFIX-hFc (Alprolix) [27] . Briefly, hFIX-mFc was generated by transient transfection in 293-F cells (Invitrogen, Carlsbad, CA, USA) and the desired heterodimers (1 hFIX-mFc and 1 mFc) were purified from the media by column chromatography [27] .
Surface plasmon resonance
Surface plasmon resonance (SPR) experiments were performed on a Biacore 3000 instrument (GE Healthcare, Marlborough, MA, USA) with histidine-tagged recombinant mouse and human FccR (R&D Systems, Minneapolis, MN, USA) and FcRn (Sino Biological) immobilized on a CM5 chip [28] .
Animal studies C3H/HeJ FIX-deficient HB mice were obtained from Dr Roland W. Herzog (University of Florida) [29] . HB mice (8) (9) (10) (11) (12) 
Inhibitory antibodies
Anti-FIX inhibitory antibody levels were determined by the Nijmegen-Bethesda assay [30] . Briefly, hFIX (0.625mIU) was diluted in normal FIX-deficient mouse plasma and incubated with heat-treated (56°C for 30 min) plasma samples for 1 h at 37°C. hFIX activity was then measured by Biophen FIX chromogenic assay (Aniara Diagnostica, West Chester, OH, USA). Inhibitory antibody levels were expressed as Bethesda Units (BU) mL À1 (50% inhibition equals 1 BU mL À1 ). 
Statistical analysis
All statistical analyses were performed with GraphPad Prism software. Statistical comparisons between experimental groups were assessed by Student's two-tailed t-test, Fisher's exact test or two-way ANOVA. Differences were considered significant and reported with *P ≤ 0.05, **P ≤ 0.01 and ***P ≤ 0.001.
Results
Generation of recombinant chimeric hFIX-mFc
We engineered a pure chimeric recombinant hFIX-mFc protein, containing the mouse IgG2a Fc-fragment, a functional homolog to human IgG1 Fc (used in Fc-fusion drugs) with specific activity identical to Benefix (Figure S1 ). To validate the functional homology between the mIgG2a and hIgG1 Fc domains when fused with FIX, we measured binding affinities of hFIX-mFc and hFIXhFc to immobilized murine and human FcRn and FccR. Both hFIX-fusion proteins bound with high affinity to murine FcRn and with similar affinity to the human FcRn (Table 1 , Figure S2 ). The hFIX-mFc and the hFIX-hFc showed the expected relative binding affinities for the high-to-low affinity Fcc-receptors, confirming the functional homology between the murine IgG2a and human IgG1 Fc domains (Table 1 , Figure S3A , S3B upper panel, respectively). However, the hFIX-hFc binding affinities to murine activating FccRs were one to two orders of magnitude lower than the hFIX-mFc affinities, stressing the importance of using species-specific Fc-fusion proteins in animal studies (Table 1 , Figure S3A , S3B lower panel, respectively).
Anti-FIX IgG antibody responses
Titers of anti-FIX antibodies were evaluated in hFIX-or hFIX-mFc-treated HB mice following the fourth and fifth IV treatments. An earlier time-point (second IV) showed no detectable anti-FIX response (data not shown). After four infusions, mice treated with hFIX-mFc had significantly higher anti-FIX IgG titers compared with hFIXtreated mice (Fig. 1A, left) . However, following the fifth IV infusion, differences in anti-FIX IgG titers between treatment groups were no longer significant (Fig. 1A , right). For both groups, anti-FIX IgG titers did not vary when determined using hFIX-or hFIX-mFc as the antigen ( Figure S4A ). However, a control group treated with the drug hFIX-hFc showed significant higher anti-hFIXhFc titers compared with the anti-hFIX titers (Figure S4B ), suggesting a strong response to the human Fc. This finding stresses the importance of using the chimeric hFIX-mFc in this study using a mouse model. We also compared titers of neutralizing ADAs (inhibitors) in both treatment groups using the NijmegenBethesda assay. HB mice treated with hFIX-mFc had significantly higher levels of inhibitors compared with hFIX-treated mice following both the fourth and fifth IV treatments (Fig. 1B) . In clinical practice ≥ 30% inhibition of FIX activity is typically used to identify an inhibitorpositive patient [30] . We used a more stringent cut-off point of ≥ 50% inhibition of FIX activity to classify animals as inhibitor-positive. After four IV injections, only hFIX-mFc-treated mice were positive for inhibitory antibodies (28.6%) (Fig. 1C, left) . Moreover, following five IV injections, the percentages of mice that were inhibitorpositive in the hFIX and hFIX-mFc-treated groups were 28.6% and 64%, respectively (Fig. 1C, right) . However, the increased risk of inhibitor development in the hFIX-mFc-treatment group was not adequately powered to establish statistical significance.
To evaluate the long-term memory and anamnestic humoral response, previously treated HB mice were rechallenged with hFIX 5 months after the last infusion. The treatment regimen and outcomes measured are illustrated in Fig. 2(A) . To identify only memory B cells, splenocytes isolated from re-challenged mice were stimulated in vitro with the TLR7/TLR8 agonist Resiquimod (R-848) in the presence of IL-2 to induce differentiation of memory B cells into antibody-secreting cells [31] . This in vitro stimulation induced an approximately 4-fold increase in the percentage of CD19 + B cells (Fig. 2B ) and a 15-20-fold increase in the percentage of antibody-secreting (Fig. 2C) . The number of FIX-specific memory B cells (as a fraction of all splenic B cells) was determined by ELISPOT and found to be similar in both groups (Fig. 2D) . Upon re-challenge, hFIX-mFc-treated mice had elevated, although not significantly different, anti-FIX IgG titers compared with hFIX-treated mice (Fig. 2E) , consistent with our previous observations (Fig. 1A, right) .
Plasma IgE and cytokine levels
Several reports have shown that prolonged (≥ 2 months) hFIX treatment of HB mice (when backcrossed onto the C3H/HeJ background [32, 33] ) leads to the development of anti-FIX IgE responses and high rates of fatal anaphylaxis [25, 26] . In this 5-week treatment regimen, we observed several fatal anaphylaxis responses only in the group treated with hFIX. Therefore, we investigated what effect, if any, Fc fusion would have on the development of IgE responses. We compared IgE titers in mice that received five weekly IV injections of hFIX or hFIX-mFc as well as untreated controls. Plasma from hFIX-treated mice showed significantly higher average IgE titers compared with hFIX-mFc or untreated mice (Fig. 3A) . Moreover, compared with hFIX-mFc-treated mice, a significantly larger proportion of hFIX-treated mice demonstrated elevated (defined as > 3 SEM above baseline) IgE titers (54% vs. 20%; P = 0.0027) (Fig. 3B) . These data suggest that repeated IV hFIX treatments lead to elevated total IgE titers, whereas Fc fusion may modulate this response. We could not measure the presence of FIX-specific IgE in the plasma, probably because of the short half-life of plasma IgE and the limited sensitivity of ELISA assays.
IgE antibodies are a hallmark of Th2-type immune responses. Antibody class switching leading to these responses is orchestrated by a cytokine-secreting differentiated Th2 CD4 + T helper cell subpopulation, which exerts a suppressive effect on Th1-type responses. In general, Th1-associated cytokines (i.e. IL-12 and IFNc) are essential for cell-mediated immune responses, whereas Th2-type cytokines (i.e. IL-4, IL-5, IL-10 and IL-13) are associated with the control of humoral immune response as well as IgE-mediated allergy [34] . Treatment with either hFIX or hFIX-mFc induced elevated levels of IL-1, IL-2, IL-10, TNFa and GM-CSF, with no significant differences between the two treatment groups (Table 2) . However, hFIX-mFc-treated mice showed a significant increase in plasma IFNc, a Th1-associated cytokine (Fig. 3C, Table 2 ). This group also showed considerably elevated IL-12 p70 plasma levels (2.2-fold over hFIX-treated mice), although the difference was not statistically significant (Fig. 3D, Table 2 ). Furthermore, in hFIXmFc-treated mice, there was a negative correlation between IFNc and total IgE levels (Fig. 3E) . Collectively, these findings suggest that hFIX-mFc treatment may skew the anti-FIX response towards the Th1 pathway, characterized by elevated IFNc and lower IgE levels.
Cytokine responses by effector/memory CD4 + T cells in vitro
To study the effect of hFIX and hFIX-mFc on CD4 + T-cell differentiation, splenocytes from treated mice were harvested 1 week after the fifth IV injection. Purified splenic CD4 + T cells were co-cultured with MHCII + APC in vitro and re-stimulated with hFIX, hFIX-mFc or Concanavalin A (ConA). Upon re-stimulation, CD4 + T cells from hFIX-treated mice secreted significantly higher levels of IL-4 and IL-10 compared with cells from hFIXmFc-treated animals, whereas hFIX-mFc-treated mice secreted significantly more IFNc (Fig. 4A) . Upon low concentration polyclonal ConA stimulation, splenic CD4 + T cells isolated from hFIX-treated mice secreted significantly higher amounts of IL-4, IL-5 and IL-10, whereas cells from hFIX-mFc-treated mice secreted significantly higher levels of IFNc (Fig. 4B) . Other cytokines not specifically associated with Th1/Th2 differentiation (IL-2, GM-CSF and TNFa) were secreted at comparable levels regardless of previous in vivo antigen exposure (Fig. 4C ). These findings demonstrate that upon exposure to polyclonal stimulation, the secreted cytokine profile reflected the dominant effector memory CD4 + T-cell population in each treatment group [35] . These data are consistent with the induction of Th2-type responses to hFIX and Th1-type responses to hFIX-mFc.
Binding to canonical FccR and the impact on antigen presentation
Interactions with cell surface Fc receptors may play an important role in antigen presentation and the induction of the T helper cell differentiation [19, 21] . We used flow cytometry to evaluate hFIX-mFc binding to FccRs on the surface of splenocytes. hFIX-mFc, but not hFIX, bound specifically to professional APC, The difference in mean FIX-specific B-cell numbers between the two treatment groups was evaluated using Student's two-tailed t-test (P = 0.7104). (E) Average anti-FIX IgG concentrations for hFIX or hFIX-mFc-treated HB mice during initial treatment and following IP hFIX re-challenge (5 months after the last IV treatment). The difference in mean titers between the two treatment groups was evaluated using Student's two-tailed t-test with a significant P value for anti-FIX IgG after four IV treatments (P = 0.0203). Anti-FIX IgG was not detected in previously untreated HB mice immunized IP with hFIX. IFNγ (pg mL -1 ) Fig. 3 . Plasma levels of IgE, IFNc and IL-12 p70 are differentially affected by treatment with human factor IX (hFIX) and hFIX fused to mouse IgG2a-Fc (hFIX-mFc). Titers of plasma IgE were measured by ELISA as described in Methods. Plasma concentrations of IFNc and IL-12 p70 were determined using the 10 Plex Bio-Plex assay as described in Methods. Sex and age-matched hemophilia B (HB) mice were treated with hFIX or hFIX-mFc via weekly intravenous (IV) infusions for 5 weeks, supplemented with anti-histamine and anti-platelet-activating factor following the fourth IV infusion. All measurements were performed 1 week after the fifth IV infusion. (A, B) Plasma IgE data were compiled from five independent experiments (hFIX, n = 48; hFIX-mFc, n = 25; untreated pretreatment plasma pools, n = 8). Mice were injected with 3-15 nmol of hFIX or hFIX-mFc. Preliminary experiments showed no differences in the humoral immune response to hFIX at this dosing range. (A) Mean IgE concentrations (horizontal bars) were compared in the two treatment groups and were higher in the hFIX-treated group (Student's two-tailed t-test, P = 0.0053), (B) Percentages of mice with total IgE levels three SEM above baseline (IgE concentration in untreated HB mice) were compared between the two treatment groups and showed elevated levels in the hFIX-treated group (Fisher's exact test, P = 0.0027). Plasma concentrations of (C) IFNc (Student's 2-tailed t test, P = 0.0392) and (D) IL-12 p70 (Student's two-tailed t-test, P = 0.0820) after five IV infusions were both higher in the hFIX-mFc-treated group. Note, the background IFNc level in pooled plasma from untreated HB mice was 5.2 pg mL À1 , whereas no IL-12 p70 was detected. (E) A correlation between IFNc and total IgE levels in the plasma of hFIX-mFc-treated mice after five IV infusions was determined by linear regression and showed a negative correlation. The baseline IgE concentration in pretreated mice was 549 ng mL À1 . Note, there was no correlation between IFNc and IgE levels in the hFIX-treated group (r = 0.3244; P = 0.2795).
with FccR-blocking 2.4G2 antibody (Fig. 5A ). There was no detectable binding to B220 + B cells or CD3 + T cells ( Figure S5D ). Interestingly, hFIX-mFc bound FccR on both CD8 -and CD8 + DC subpopulations ( Figure S5E) .
To address the impact of Fc fusion on FIX antigen presentation, we compared in vitro FIX-specific CD4 + effector T cell IL-2 responses upon presentation of soluble hFIX or hFIX-mFc by MHCII + APC. Only hFIX-mFc could stimulate significant CD4 + T cell IL-2 secretion, regardless of previous in vivo antigen exposure (Fig. 5B) . To validate this finding, we tested IFNc responses of splenic cells from mice immunized with hFIX or hFIX-mFc. We measured the number of IFNcsecreting cells in response to presentation of soluble hFIX or hFIX-mFc by ELISPOT. In vitro re-stimulation with hFIX-mFc elicited significantly higher IFNc secreting cells from both hFIX-and hFIX-mFc-immunized mice, whereas re-stimulation with hFIX did not induce an appreciable response (Fig. 5C ). Our data on the engagement of hFIX-mFc with the canonical FccR and the enhancement of antigen presentation provide a plausible mechanistic explanation for the ability of the Fc domain to modulate the type of anti-FIX immune response.
Discussion
Advances in our understanding of Fc biology suggest that the considerable clinical advantages of Fc-fusion drugs could be tempered by immunological adverse reactions [36, 37] . An appropriate animal model is necessary to understand the immunological mechanisms and pathways influenced by Fc-fusion proteins. Fc interactions are complex and the affinities of the Fc moiety to a large repertoire of receptors are key determinants of biological outcomes, which can be either activating or regulatory. We have measured the affinities of hFIX-mFc and hFIXhFc to several Fcc receptors (Table 1) . Compared with the mFc, the affinity of the hFc moiety is considerably lower for the murine Fcc receptors (often by 1-2 orders of magnitude). Moreover, treatment with hFIX-hFc induced a strong immune response to the hFc (Figure S4B) . Thus, in a mouse model it is important to study the murine surrogate of the human FIX-hFc proteindrug, namely hFIX-mFc.
Using an hFIX-mFc chimeric protein in a HB mouse model we show that Fc fusion can change the antibody immune response (Fig. 1) . The group treated with hFIXmFc showed significantly higher anti-FIX IgG titers early in the treatment regimen and concomitant onset of FIX inhibitors. With one additional infusion, both hFIX and hFIX-mFc elicited comparable anti-FIX IgG titers, but the inhibitory response in terms of BU levels and percentage of inhibitory-positive mice remained higher in the hFIX-mFc-treated group. This might stem from higher affinities or different epitope specificities of the antibodies induced by hFIX-mFc treatment.
Our studies on the engagement of hFIX-mFc with activating FccR expressed by professional APC (DC and MΦ) offer a mechanistic basis for these differences. Binding of the Fc moiety would allow targeting of the FIX antigen to APC and enhanced presentation and priming of CD4 + T cells, which can trigger an earlier onset of immunity. We show that in vitro presentation to FIX-specific CD4 + T cells is productive only when FIX is fused to mFc (Fig. 5) . Binding of Fc-fusion drugs to human soluble and cellular FccRs has been reported by others [38] [39] [40] [41] ; however, these studies did not evaluate all the canonical FccR and cell types.
Fc-FcR interactions in terms of binding and signaling can be 'fine-tuned' by the degree of Fc aggregation. We suggest that early onset of anti-FIX antibodies and the weekly administration of hFIX-mFc can generate immune complexes (ICs) with high Fc avidity as a result of the additional contribution of the fusion drug's Fc domain. ICs bind with higher avidity to FccR and deliver activating signals that induce an immunomodulatory response [21, [42] [43] [44] [45] . However, ICs can also attenuate the immune response via the inhibitory FccRIIB or through ITAMdependent and ITAM-independent inhibitory mechanisms via the activating FccRs [46] [47] [48] [49] [50] [51] . ICs may also lead to rapid clearance of the weekly infused FIX antigen and prevent re-boosting of memory B cells [52] . An additional mechanism was described recently where chronic viral infection induced immune exhaustion through constant occupation of the FccR by ICs [53] [54] [55] . These inhibitory mechanisms may have a modulating effect on the anti-FIX humoral response, resulting in a poor anamnestic response in both treatment groups (Fig. 2) . Our results are consistent with studies on other Fc-fusion drugs (etanercept and belatacept) reported to trigger early ADA responses, which disappeared with the progression of treatment [56, 57] . However, these drugs are poor models for studying the immune consequences of Fc fusion as the active moiety in both drugs suppresses immune and inflammatory pathways.
Several lines of evidence (Fig. 6 ) are presented here to support the conclusion that Fc fusion shifts the anti-FIX CD4 + T-cell response from Th2 to Th1. Previous studies in this mouse model have shown that hFIX treatment results in increased IgE levels [25] . Here we replicate this phenomenon (Fig. 3) and show that FIX-specific effector CD4 + T cells secrete higher levels of Th2-associated cytokines upon in vitro re-stimulation (Fig. 4) . In contrast, treatment with hFIX-mFc results in a significantly attenuated IgE response compared with hFIX-treated mice (Fig. 3) . The immune response to hFIX-mFc is characterized by significantly higher Th1-associated IFNc plasma levels, as well as in vitro cultures of re-stimulated FIX-specific effector memory CD4 + T cells (Figs 3-4 ; Table 2 ). The negative correlation between IgE levels and IFNc in the hFIX-mFc-treated group demonstrates a mutual Th2/Th1 inhibition. Studies using FcRc À/À mice, which produced higher titers of IgE upon immunization compared with WT mice [58] , also support our findings. Additionally, mice immunized with Fc fused to pathogenderived antigens or chemokine ligands, or with monoclonal antibody bacteria ICs, have shown enhanced protective T-cell and humoral responses, IFNc secretion [59] [60] [61] [62] and abrogated IgE responses [59, 62] . A subset of HB patients on FIX replacement therapy, with high levels of inhibitory antibodies are at risk of developing anti-FIX IgE responses and resultant anaphylactic reactions [10, 11, 63] . The HB mouse model used in this study is appropriate for investigating this phenomenon because it has been previously demonstrated that these mice are predisposed to develop an IgE response and fatal anaphylaxis following long-term treatment with hFIX [25, 26] .
The priming of na€ ıve CD4 + T cells and activation of effector memory CD4 + T cells are dependent on professional APCs that internalize and process antigens, present MHC II/peptide complexes to T-cell receptors (TCR) and deliver co-stimulatory signals. The strength of TCR signaling by MHC II/antigen complexes can dictate the differentiation of na€ ıve CD4 + T cells toward Th1 or Th2 [64] . High antigen concentration and availability delivers strong TCR signaling directing undifferentiated naive CD4 + T cells to acquire a Th1 phenotype, whereas weak signaling induces a Th2 phenotype [64, 65] . Our findings (Figs 3-4 ; Table 2) suggest that the Fc fusion promotes strong TCR signaling and Th1-biased immune responses via several plausible mechanisms. The Fc domain extends the availability of FIX in vivo via FcRn, which has been shown to enhance antigen presentation [66] [67] [68] [69] [70] . The engagement of FIX-Fc monomers ( Fig. 5 ; Table 1 ) with activating FccRs on DC and MΦ can lead to efficient antigen presentation to CD4 + T cells [21, 60] . Signaling via activating FccR can also result in the secretion of the cytokine IL-12 by MΦ and DC, which contribute to the Th1 pathway [21, 60] . We found elevated plasma IL-12 p70 in hFIX-mFc-treated HB mice ( Fig. 3 ; Table 2 ). Another promoter of the Th1 pathway is IFNc, which up-regulates the expression of MHCII, FccR and co-stimulatory molecules by DC and MΦ, enhancing their antigen presentation [21, 34] . The primary producers of IFNc upon activation are the innate immune cells NK and NKT, which express activating FccR involved in their activation [71] . We show that hFIX-mFc binds to NKT cells, suggesting an early source of IFNc (Fig. 5A) . A summary of mechanisms contributing to the distinct immune responses in mice treated with hFIX or hFIXmFc is illustrated in Fig. 6 .
Recent studies using mouse models, triggered by observations in patients treated with monoclonal antibodies or Fc-fusion drugs, reveal the beneficial and adverse effects of Fc-FccR interactions. For example, it was shown that treatment of immune thrombocytopenia with an antiFccR drug is associated with adverse effects, as a result of FccR activation [72] . In contrast, murine studies suggest that high-affinity interaction of the Fc domain of monoclonal antibodies and Fc-fusion drugs with FccR contributes to the effect of treatment [18, 73] . Thus, it is important to note that Fc-FcR affinities are influenced by both the Fc moiety and the active drug [73, 74] .
Taken together, our study suggests that an animal disease model in conjunction with an appropriate fusion protein can be useful in understanding how Fc fusion is likely to influence immunological responses to a protein therapeutic. Fc biology is complex; therefore, the immunological pathways activated and/or attenuated also depend on both partners in the fusion protein. Thus, it is difficult to generalize based on studies on a specific Fctherapeutic protein combination and each fusion protein should be individually studied. 
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